ABSTRACT
BACKGROUND: Coronavirus disease 19 (COVID-19), an infectious disease resulting from a virus known as severe acute respiratory syndrome coronavirus 2 (SARS-COV-2), was discovered in China in 2019 and causes several mild to moderate respiratory conditions. This study aimed to reveal the changes in serum interleukin-10 (IL-10) and other parameters in Iraqi COVID-19 patients compared with healthy controls by studying the effects of enoxaparin and evaluating the potential of IL-10 as a disease activity marker. METHODS: This was a case-control study that included 180 samples: 90 patients hospitalized with COVID-19 from November 2022 to 20 April 2023 (40 patients had never used enoxaparin, whereas 50 patients had taken enoxaparin) and 90 healthy, age- and sex-matched control. There were 44 female patients and 46 male patients. The mean age of the patients and controls was 53.8 years vs. 50.8 years, respectively. The sandwich enzyme-linked immunosorbent assay (ELISA) method was used to measure IL-10 levels, while other parameters were assessed using the colorimetric method. RESULTS: The results of the study indicated highly significant changes between the patients and healthy controls in IL-10, D-dimer, and C-reactive protein (CRP) levels, as well as liver and renal functions. These findings elucidated a significant change between enoxaparin patients and non-enoxaparin patients in IL-10, D-dimer, and CRP levels. However, the liver and renal functions were not significantly altered. The Spearman's rank correlation test investigated the relationship between serum IL-10 and CRP. CONCLUSIONS: The results displayed a strong positive relationship between IL-10 and CRP. There were no significant differences between the other analyzed parameters; consequently, the patients had higher concentrations of IL-10, D-dimer, and some other parameters than the healthy controls. Additionally, IL-10 may be used as a marker of disease activity. Enoxaparin will likely help control IL-10 and D-dimer concentrations in patients since IL-10 levels decreased in patients treated with enoxaparin.
Subject(s)
COVID-19 , Enoxaparin , Interleukin-10 , Humans , Interleukin-10/blood , Enoxaparin/therapeutic use , Male , Female , Case-Control Studies , COVID-19/blood , Middle Aged , Iraq , Adult , C-Reactive Protein/metabolism , C-Reactive Protein/analysis , SARS-CoV-2 , Biomarkers/blood , COVID-19 Drug Treatment , Anticoagulants/therapeutic use , Fibrin Fibrinogen Degradation Products/metabolism , Fibrin Fibrinogen Degradation Products/analysis , AgedABSTRACT
Herein, we report a facile process for the preparation of styrene and methyl-methacrylate copolymer nanocomposites containing reduced graphene oxide and silver nanoparticles ((R-(GO-(PS-PMMA))/AgNPs)) by using (i) microwave irradiation (MWI) to obtain R-(GO-(PS-PMMA))/AgNPs and (ii) the in situ bulk polymerization technique to produce RGO/AgNPs-(PS-PMMA). Various characterization techniques, including FT-IR, XPS, Raman spectroscopy, XRD, SEM, HR-TEM, DSC, and TGA analysis, were used to characterize the prepared nanocomposites. The Berkovich nanoindentation method was employed to determine the hardness and elastic modulus of the nanocomposites. The results showed that the MWI-produced nanocomposites were found to have enhanced morphological, structural, and thermal properties compared with those of the nanocomposites prepared by the in situ method. In addition, the antibacterial activity of the prepared nanocomposites against the E. coli HB 101 K-12 was investigated, whereby an inhibition zone of 3 mm (RGO/AgNPs-(PS-PMMA) and 27 mm (R-(GO-(PS-PMMA))/AgNPs) was achieved. This indicates that the MWI-prepared nanocomposite has stronger antibacterial activity than the in situ-prepared nanocomposite.
